Dexilant not an 'Innovative Drug' under Canada's Food and Drug Regulations: Majority of Federal Court of Appeal
Journal of Intellectual Property Law & Practice, Forthcoming
6 Pages Posted: 21 Feb 2013 Last revised: 24 Feb 2013
Date Written: February 20, 2013
Abstract
In Takeda Canada Inc. v. Canada (Health), 2013 FCA 13, a majority of the Federal Court of Appeal refused to list Takeda’s acid reflux drug, Dexilant, as an 'innovative drug' under Canada’s Food and Drug Regulations.
Keywords: data, protection, innovative, drug, pharma, Canada, Dexilant, NAFTA, TRIPS, Federal Court, FCA
Suggested Citation: Suggested Citation
Crowne, Emir and Moazzam, Lida, Dexilant not an 'Innovative Drug' under Canada's Food and Drug Regulations: Majority of Federal Court of Appeal (February 20, 2013). Journal of Intellectual Property Law & Practice, Forthcoming , Available at SSRN: https://ssrn.com/abstract=2221674
Do you have negative results from your research you’d like to share?
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.